A Placebo-Controlled, Randomized Study on the Impact of Dietary Salmon Protein Hydrolysate Supplementation on Body Mass Index in Overweight Human Subjects

Bomi Framroze¹*, Sanjay Vekariya² and Dhruv Swaroop³
¹R&D Department, Hofseth Biocare AS. Molovegen, Norway
²Spectrum Clinical Research, 37 New Marine Lines, Mumbai 400020, India
³GenePrint Health LLP, 4 Henry Road, Mumbai 400001, India

Abstract

In the article, we show that a daily dietary intake of 16 g of salmon protein hydrolysate powder for 42 days statistically significantly reduced Body Mass Index by 5.6% in overweight subjects, in comparison with a placebo-control of whey protein isolate. Four metabolism-relevant serum biomarkers - bile acid, interleukin-6, Preheparin lipoprotein lipase mass and adiponectin - were also positively impacted using one-tailed, paired student t-test analysis, leading to the proposed metabolism-elevating mode-of-action. Exercise levels were maintained for each subject as per their normal levels. Further research will seek to identify the active individual peptide components from the salmon protein hydrolysate with specific biological activity for obesity control. Salmon protein hydrolysate powder in supplemental doses may be a useful tool in the long-term management of obesity.

Keywords: Salmon; Protein; Hydrolysate; Obesity; Bile acid; Adiponectin

Introduction

Obesity is a major global health problem with over 3 million adults dying each year from obesity related complications [1]. Overweight and obese individuals with abnormal or excessive fat accumulation are at increased risk of type-2 diabetes, [2] cardiovascular disease [3] and metabolic disorders, particularly cancer [4].

Most efforts to overcome obesity have focused on developing anti-obesity drugs such as fenfluramine for reducing energy intake, or hunger suppressants such as dexfenfluramine and satiety signalers such as sibutramine [5]. However, the few drugs that have entered the market are not widely used and are associated with serious side effects including insomnia, dry mouth, constipation, nausea and headache [6]. By contrast, functional foods are generally considered safe for clinical use, [7] and are being increasingly studied under clinically validated conditions. High whey-protein powders combined with low carbohydrate diets have been shown to reduce Body Mass Index (BMI) and increase metabolic responses [8]. A high-protein diet with casein has similarly shown a fat reducing effect, but had no impact on metabolic markers such as adiponectin, leptin and insulin, [9] while soy proteins have been shown to assist with dyslipidaemia and atherosclerosis prevention [10]. Most research efforts on marine protein hydrolysate powders such as those from krill [11] and fish [12] have focused on the reduction of plasma triacylglycerol levels and other cardiovascular biomarker benefits [13]. Some newer research has begun to expand the role of fish protein hydrolysates in metabolism and digestive modulation by showing an increase in plasma bile acid production [14], reducing adiposity [15], antihypertensive effect [16], antioxidant effect [17] and immunological effects [18] in animal and human trials. Other researchers have also shown the potential of various protein hydro lysates in impacting metabolism and weight reduction. Morifuki et al. [19] have described an increase in muscle glycogen levels with whey hydro lysates probably related to the faster digestibility of the protein. Van Baak et al. [9] have shown that whey protein hydro lysates have modest fat mass reducing effects; but no relevant biomarkers, such as adiponectin or leptin, showed a corresponding metabolism increase correlation. More recently, Marette et al. [20] have shown that genetically modified mice fed a high-fat diet that included salmon protein hydrolysate (SPH showed a reduction in metabolic syndrome (MetS) as measured by glucose-intolerance and inflammation reduction. Significantly, all these studies only showed fat mass losses when the whey or fish protein hydro lysates were used as a significant component of the dietary protein source (50 g-140 g per day) and in conjunction with a low carbohydrate diet.

Our research has instead focused on identifying bioactive peptides present within SPH powder that may activate different metabolic pathways to increase fat burn at non dietary supplement dosing (4 g-16 g per day) when included as part of a normal diet. Our own recently published results on the ability of enzymatically hydrolyzed SPH powder to increase haemoglobin concentration in situationally anaemic human subjects at only 14 g per day supplemental dosing have shown the presence of such bioactive peptides already [21]. Based on this and our earlier encouraging results from animal studies, which showed an increase in bile-acid production in rats fed 2 g of SPH per day, we carried out this clinical trial to evaluate the potential anti-obesity, increased fat burning effect of enzymatically liberated SPH protein powder on overweight human subjects and its effect on the four metabolism biomarkers shown below.

Plasma fatty acid (FA) composition is modulated by dietary intake and its composition has been associated with various health outcomes [22]. Bile acids are essential for solubilization of dietary fats [23]. Bile acids are synthesized in the liver and secrete through the biliary tree into the gall bladder. From the gall bladder the bile acids are secreted into the small intestine for digestion and are eventually reabsorbed and

*Corresponding author: Bomi Framroze, R&D Department, Hofseth Biocare AS. Molovegen 6, 6004, Alesund, Norway, Tel: 47 70 10 26 30; E-mail: bf@hofsethbiocare.no

Received December 21, 2015; Accepted January 12, 2016; Published January 15, 2016


Copyright: © 2016 Framroze B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
returned to the liver. Bile acids have been reported to reduce plasma and liver triacylglycerol (TG) levels in animal and human trials [24]. A high plasma concentration of TG is a characteristic feature of reduced metabolic activity and increased risk of Cardio-Vascular Disease (CVD). The reduction of plasma TG coupled with lowered metabolic activity via increased plasma BA is a relevant clinical goal to treat mild obesity [25]. Furthermore, glucose metabolism also seems to be regulated by increased circulatory bile acid [26]. Thus an increase in plasma bile acid levels could be viewed as a positive biomarker for the treatment of obesity.

Human Interleukin 6 (IL-6) is a 184 amino acid polypeptide. It is produced by various cells, including T- and B-cells, monocytes, fibroblasts, keratinocytes and endothelial cells. It regulates the growth and differentiation of various cell types with major activities in the immune system, metabolism, and inflammation [27]. Most normal controls have low levels of IL-6 in their serum. Increases of IL-6 are detected 97 in severe inflammatory situations, such as septicemia, and in metabolic and autoimmune diseases, such as arthritis and obesity [28]. The reduction of circulating IL-6 could be viewed as a biomarker to detect an improvement in underlying metabolic disorder during treatment for obesity.

Preheparin Lipoprotein lipase (Pr-LPL Mass) is a lipolytic enzyme involved in catalyzing the hydrolysis of triglycerides in chylomicrons and very low density lipoprotein (VLDL) particles [29]. It is regulated by insulin and its serum level reflects insulin sensitivity [30]. Pr-LPL mass has also been used to assess insulin sensitivity in the general population and in advanced Type II diabetic patients [31]. Studies have shown that pre-heparin serum LPL mass has significant relationships with serum lipids and lipoproteins, visceral fat area, insulin resistance, and the development of CVD [32], and that an increase in its serum levels could be reflective of a decrease in visceral fat levels upon intervening dietary treatment for obesity.

The metabolic syndrome, a cluster of abdominal obesity, dyslipidemia, hypertension and hyperglycemia, is a common basis for atherosclerotic vascular diseases in industrial countries exposed to over nutrition [33]. Adiponectin is an adipose-derived plasma protein with anti-atherogenic and insulin-sensitizing activities [34]. Hypoadiponectinemia is closely associated with the clinical phenotype of metabolic syndrome and observing an elevated plasma concentration of adiponectin [35] may be a useful biomarker for measuring the effectiveness of dietary treatment for obesity.

The objective of this study was to measure the change in fat burn through Body Mass Index (BMI) without any change in the level of exercise for each subject and observe any changes in the related metabolic biomarkers of bile acid, interleukin-6, preheparin lipoprotein lipase mass and adiponectin after 42 days of SPH powder supplementation in overweight people using a randomized, placebo-controlled protocol.

Methods and Materials

Study design and Subjects

The objective of this prospective, open, randomized study was to determine the dietary effects of salmon protein hydrolysate on decreasing BMI with commensurate modulation of circulatory levels of the metabolic biomarkers of bile acid, interleukin-6, preheparin lipoprotein lipase mass and adiponectin in overweight subjects. This study was conducted in accordance with the principles of the Declaration of Helsinki guidance for good clinical practice, Seoul 2008 and Good Clinical Practices guidelines for clinical research in India, ICMR. The final approved protocol and all the study related documents were reviewed and approved by the ClinXXL Independent Ethics Committee before the start of the study.

Salmon protein hydrolysate tablets were sourced from Pharmatech AS, Rolvsøy, Norway and Whey Protein Hydrolysate powder was sourced from Protein Fabrikken AS, Stokke, Norway. 48 human subjects between the ages of 18 and 65 with overweight BMI values between 25 and 30 were recruited for the study. 143 Subjects who were already on specific diet recommendations, on caloric reduction diets or other special diets were excluded from this study. Subjects who had uncontrolled diabetes, coronary artery disease, cardiovascular disease and coronary atherosclerosis or uncontrolled hypertension were also excluded. Subjects with clinical signs and symptoms of liver, kidney or thyroid disorder and tuberculosis were also excluded. Alcoholics, smokers, and pregnant and lactating women were also excluded from this study.

Experimental design and procedures

The total duration of this study was 42 days. A total of 48 subjects of which female (n=37) and male (n=11) were recruited in the study. The 48 subjects were split into two study groups. Group 1 (G1) consisted of 24 overweight subjects with BMI between 25 and 30 who received 16 x 1 gram tablets of SPF to be taken daily at breakfast while maintaining their routine diets. Group 2 (G2) consisted of 24 overweight subjects with BMI levels between 25 and 30 who received 18 g powder sachets of whey protein isolate (WPI) to be taken daily at breakfast while maintaining their routine diets (Table 1).

Dietary counselling was carried out to normalize the subject pool between the two groups so that there was no significant calorie and type of foods difference in diet between them. A detailed history of food consumption was taken based on a 24-hour dietary recall method. The complete dietary history included the consumption of vegetarian and non-vegetarian food and the frequency of consumption of fish or meat was obtained for each subject. Standardized containers were used to assess the amount of food consumed. The average daily intake of major food groups, namely cereals, pulses, meat, milk, vegetables, fruits and oil was assessed, and subjects who were consuming oily rich food regularly were advised to limit the same during the study. The subjects were instucted to follow similar diets during the course of the study and to note any significant deviations during the twice weekly telephone follow-up.

At Visit 1 (Clinic Visit 1/Day -2), the pre-enrolment clinical safety assessment was carried out, which included informed consent signing, medical history review, and systemic and physical examination for all screened subjects. The subjects were only enrolled in the study after confirmation of study inclusion and exclusion criteria.

During the baseline visit (Clinic Visit 2/Day 0), the subjects were given their salmon protein tablets or their whey protein powder sachets for the study and dietary counselling was repeated by trained dieticians. Telephonic follow up for routine diet monitoring and protein hydrolysate tablets/sachet intake compliance was performed twice weekly for the entire duration of the study.

On the final day of the study (Clinic Visit 3/187 Day 42), a systemic and physical examination was carried out for each subject and a 10 ml blood sample taken for analysis of the metabolic biomarkers, bile acid, interleukin-6, preheparin lipoprotein lipase mass and adiponectin. Bile acid was measured using the colorimetric method and kits supplied...
Results

All raw data from this study was analyzed using "Sigma Plot 11.0" statistical software (Supplied by Cranes Software International Ltd. Bangalore). The mean and standard deviation was calculated using Microsoft Excel Sheets and all data summarized in tabular form. Data describing quantitative measures were expressed as mean, SD with range. Changes in variables were estimated by analysis of variance. All p values were reported based on two sided significance test and all statistical tests were interpreted at 95% level of significance. No treatment related classical signs or symptoms were observed in any of the subjects at the end of the study period. 19 of the 23 subjects that completed the trial in G1 showed 209 a significant decrease in BMI levels such that the mean BMI level for G1 showed a statistically significant 5.9% decrease from baseline at Day 42. Only 6 out of the 24 subjects in G2 showed a very modest decrease in BMI levels such that the decrease in mean BMI level for G2 was not statistically significant, as shown below in Table 2.

The plasma bile acid levels were found to be significantly increased for the SPH treated group G1 versus the WPI treated group G2 as shown below in Table 3. At the end of the 42-day study, the SPH test group showed a statistically significant increase in plasma bile acid concentration (from a normal baseline of 2.0 μM/L to 6.9 μM/L) as compared to the WPI control group, which did not show a statistically significant increase (from 6.6 μM/L to 6.7 μM/L). The mean serum IL-6 levels were found to be at the upper end of the normal range among the recruited subjects, 1 subject was prematurely discontinued from the study due to reasons not related to the protein powder. A total of 47 subjects completed the study as per the protocol.

Discussion

The standard of care for overweight individuals is to suggest exercise and diet, which, if ineffective, quickly leads to clinical obesity, defined as a BMI greater than 30. At this point, the standard of care

Clinical signs or symptoms were observed in any of the subjects at the end of the study period. All raw data from this study was analyzed using "Sigma Plot 11.0" statistical software (Supplied by Cranes Software International Ltd. Bangalore). The mean and standard deviation was calculated using Microsoft Excel Sheets and all data summarized in tabular form. Data describing quantitative measures were expressed as mean, SD with range. Changes in variables were estimated by analysis of variance. All p values were reported based on two sided significance test and all statistical tests were interpreted at 95% level of significance. No treatment related classical signs or symptoms were observed in any of the subjects at the end of the study period. 19 of the 23 subjects that completed the trial in G1 showed 209 a significant decrease in BMI levels such that the mean BMI level for G1 showed a statistically significant 5.9% decrease from baseline at Day 42. Only 6 out of the 24 subjects in G2 showed a very modest decrease in BMI levels such that the decrease in mean BMI level for G2 was not statistically significant, as shown below in Table 2.

The plasma bile acid levels were found to be significantly increased for the SPH treated group G1 versus the WPI treated group G2 as shown below in Table 3. At the end of the 42-day study, the SPH test group showed a statistically significant increase in plasma bile acid concentration (from a normal baseline of 2.0 μM/L to 6.9 μM/L) as compared to the WPI control group, which did not show a statistically significant increase (from 6.6 μM/L to 6.7 μM/L). The mean serum IL-6 levels were found to be at the upper end of the normal range among the recruited subjects, 1 subject was prematurely discontinued from the study due to reasons not related to the protein powder. A total of 47 subjects completed the study as per the protocol.

Discussion

The standard of care for overweight individuals is to suggest exercise and diet, which, if ineffective, quickly leads to clinical obesity, defined as a BMI greater than 30. At this point, the standard of care

Clinical signs or symptoms were observed in any of the subjects at the end of the study period. All raw data from this study was analyzed using "Sigma Plot 11.0" statistical software (Supplied by Cranes Software International Ltd. Bangalore). The mean and standard deviation was calculated using Microsoft Excel Sheets and all data summarized in tabular form. Data describing quantitative measures were expressed as mean, SD with range. Changes in variables were estimated by analysis of variance. All p values were reported based on two sided significance test and all statistical tests were interpreted at 95% level of significance. No treatment related classical signs or symptoms were observed in any of the subjects at the end of the study period. 19 of the 23 subjects that completed the trial in G1 showed 209 a significant decrease in BMI levels such that the mean BMI level for G1 showed a statistically significant 5.9% decrease from baseline at Day 42. Only 6 out of the 24 subjects in G2 showed a very modest decrease in BMI levels such that the decrease in mean BMI level for G2 was not statistically significant, as shown below in Table 2.

The plasma bile acid levels were found to be significantly increased for the SPH treated group G1 versus the WPI treated group G2 as shown below in Table 3. At the end of the 42-day study, the SPH test group showed a statistically significant increase in plasma bile acid concentration (from a normal baseline of 2.0 μM/L to 6.9 μM/L) as compared to the WPI control group, which did not show a statistically significant increase (from 6.6 μM/L to 6.7 μM/L). The mean serum IL-6 levels were found to be at the upper end of the normal range among the recruited subjects, 1 subject was prematurely discontinued from the study due to reasons not related to the protein powder. A total of 47 subjects completed the study as per the protocol.

Discussion

The standard of care for overweight individuals is to suggest exercise and diet, which, if ineffective, quickly leads to clinical obesity, defined as a BMI greater than 30. At this point, the standard of care
remains diet and exercise, but doctors are increasingly depending on either invasive surgery or drugs which have a myriad of side-effects [36] and often result in a relapse of weight-gain. Multiple studies have shown that both treatments may not result in long-term improved BMI and weight loss for a significant number of patients [37]. The use of functional foods to decrease BMI has seen increased research attention [38] and specific modes of action for these foods have focused on insulin regulation [39], gut micro biota rebalance [40] and modulating the metabolic syndrome [41]. One aspect of our results shows that after 8 weeks of daily, supplemental-dose administration of salmon protein hydrolysate powder in overweight subjects, it may be concluded that salmon protein hydrolysate significantly lowered BMI in overweight subjects. Our results further showed that metabolism related, circulatory biomarkers - bile acid, adiponectin, Pr-LPL Mass and Interleukin-6 - showed positive improvements, indicating that the SPH lowers BMI via interaction with the metabolic pathways. As can be seen in Figure 1, salmon protein hydrolysate, at a dose of 16 g per day, showed a statistically significant decrease in BMI and positive impacts on the key metabolic syndrome biomarkers. By contrast the whey protein isolate control had no lowering of BMI nor any significant impact on these biomarkers. This implies that the decrease in BMI may be related to a modulation of inflammation and metabolism pathways, possibly via the presence of bioactive peptides in the SPH. It is noteworthy to mention here that 83% of the subjects in the SPH treated group G1 showed a significant decrease in BMI, while only 25% showed even a modest decrease in the WPI treated G2 group.

In this initial study, we have not evaluated certain parameters that do limit the conclusions that can be drawn. We have not identified an optimum dose/period for effective treatment, or how long the effect of the SPH supplementation may last, and have not directly measured the insulin and leptin levels to better understand sugar metabolism and appetite signalling during SPH supplementation. We are planning on fractionating the 641 peptides present in the SPH powder by both size-occclusion column as well as ion-exchange chromatography to further understand the potential role played by individual bioactive peptides. This remains an active area of research in our laboratory.

Our current results clearly show that dietary supplementation with 16 g of salmon protein hydrolysate per day decreases BMI in overweight individuals and positively impacts circulatory biomarkers associated with inflammation and metabolism, within only 8 weeks of treatment.

References

Figure 1: percent change in parameters for SPH vs. WPI treatments

Nutm Neurosci 18: 49-65.


Figure 1: percent change in parameters for SPH vs. WPI treatments

Nutm Neurosci 18: 49-65.


